Metropolitan Life Insurance CO Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Metropolitan Life Insurance CO

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Jun 14, 2023	BUY	$144.95 - $152.29 $549,505 - $577,331	3,791 New	3,791 $573 Million
Q2 2022 Jun 20, 2023	BUY	$83.14 - $145.99 $312,024 - $547,900	3,753 New	3,753 $547 Million
Q1 2022 Jun 20, 2023	BUY	$110.08 - $142.92 $384,069 - $498,647	3,489 New	3,489 $414 Million
Q4 2021 Jun 21, 2023	BUY	$99.73 - $148.48 $1.41 Million - $2.1 Million	14,158 New	14,158 $1.95 Billion
Q3 2021 Jun 21, 2023	BUY	$98.85 - $138.91 $1.44 Million - $2.02 Million	14,537 New	14,537 $2.02 Billion
Q1 2021 Jun 26, 2023	BUY	$64.07 - $91.75 $836,433 - $1.2 Million	13,055 New	13,055 $892 Million
Q4 2020 Jun 22, 2023	BUY	$65.07 - $98.24 $878,770 - $1.33 Million	13,505 New	13,505 $1.16 Billion
Q3 2020 Jun 26, 2023	BUY	$59.04 - $77.95 $836,596 - $1.1 Million	14,170 New	14,170 $921 Million
Q2 2020 Jun 26, 2023	BUY	$29.01 - $74.23 $416,989 - $1.07 Million	14,374 New	14,374 $1.05 Billion
Q1 2020 Jul 12, 2023	BUY	$27.51 - $57.29 $345,112 - $718,703	12,545 New	12,545 $427 Million
Q4 2019 Jul 12, 2023	BUY	$40.86 - $57.65 $500,657 - $706,385	12,253 New	12,253 $667 Million
Q3 2019 Jul 12, 2023	BUY	$37.38 - $49.47 $470,838 - $623,124	12,596 New	12,596 $526 Million
Q2 2019 Jul 12, 2023	BUY	$39.79 - $67.01 $414,333 - $697,775	10,413 New	10,413 $456 Million
Q1 2019 Jul 13, 2023	BUY	$34.52 - $53.29 $359,456 - $554,908	10,413 New	10,413 $536 Million
Q4 2018 Jul 13, 2023	BUY	$29.75 - $42.9 $309,786 - $446,717	10,413 New	10,413 $385 Million
Q3 2018 Jul 13, 2023	BUY	$32.79 - $43.0 $341,442 - $447,759	10,413 New	10,413 $391 Million

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.